AKT1 and non-small cell lung carcinoma: However, recent emerging data has shown pAKTT308 is a more potent driver and marker of aggressive disease in non –small cell lung cancer and pAKTT308, rather than pAKTS473, correlates with AKT downstrem effectors [55].